New Antimalarials A Risk-Benefit Analysis
- 1 April 1995
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 12 (4), 264-273
- https://doi.org/10.2165/00002018-199512040-00006
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Treatment Of Multidrug-Resistant Plasmodium Falciparum Malaria With 3-Day Artesunate-Mefloquine CombinationThe Journal of Infectious Diseases, 1994
- Early treatment of malaria in the community using artemisinin—hope or hazard?Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East AfricaThe Lancet, 1993
- Comparison of artemether and chloroquine for severe malaria in Gambian childrenThe Lancet, 1992
- Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria.1991
- Halofantrine in the treatment of malaria.1989
- Sensitivity to quinine and mefloquine of Plasmodium falciparum in Thailand.1986
- Qinghaosu (Artemisinin): an Antimalarial Drug from ChinaScience, 1985
- CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM MALARIA IN THE UNITED KINGDOMThe Lancet, 1968